

NAMSDL



National Alliance for Model State Drug Laws

SUBSTITUTED CATHINONES BILL STATUS REPORT – CARRYOVER, 2013 AND SPECIAL SESSIONS AND PROPOSED REGULATIONS

This project was supported by Grant No. G1299ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States of Government.

© 2013 Research is current as of May 17, 2013. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namSDL.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

State	Bill No.	Description	Status and Date of Last Action
Arizona	H.B. 2327	Adds a-PBP, a-PPP, a-PVP, butylone, ethcathinone, ethylone, MDAI, MDPPP, MDPV, mephedrone, metamfepramone, methedrone, methylone, MOPPP, MPBP, NRG-1, pentylone, and new generic language	Signed by Governor 4/3/2013
Conn.	S.B. 121	Bans the sale of substances labeled as bath salts that have a similar effect as mephedrone and MDPV	Referred to committee 1/11/2013
D.C.	L.B. 184	Adds BZP, ephedrone, MDVP, mephedrone, methylone	Adopted 4/1/2013
D.C.	L.B. 645	Adds 3-FMC, 4-FMC, a-PPP, a-PVP, butylone, BZP, ephedrone, ethcathinone, ethylone, MDAI, MDPPP, MDPV, mephedrone, metamfepramone, methedrone, methylone, MOPPP, MPBP, NRG-1	Enacted 2/13/2013
D.C.	L.B. 1109	Adds BZP, ephedrone, mephedrone, methylone, MDPV	Signed by Mayor; effective on signing 1/14/2013
Florida	H.B. 619	Adds 4-MeMABP, pentedrone	Substituted by S.B. 294; laid on table 4/17/2013
Florida	S.B. 294	Adds 4-MeMABP, pentedrone	Approved by Governor 4/24/2013
Louisiana	H.B. 10	Adds MDAI	Sent to Governor 5/16/2013
Maine	H.P. 1033	Adds 3-FMC, 4-FMC, 4-MEC, butylone, eutylone, MDPV, mephedrone, methedrone, methylone, NRG-1, pentedrone, pentylone, and generic language	Referred to committee and ordered printed 4/24/2013
Mass.	H.B. 4383	Adds generic language, mephedrone, MDPV, methylone, methedrone, 4-FMC, 3-FMC, HMMC, MPBP, ephedrone, 4-EMC, 3,4-DMMC, a-PVP, NRG-1, butylone, pentylone, eutylone, MDAI, ethcathinone, metamfepramone, a-PPP, MOPPP, MDPPP, buphedrone, MDPBP	No further action taken 1/1/2013
Montana	H.B. 140	Adds generic language	Signed by Governor 4/2/2013
New York	A.B. 717	- adds generic language - requires commissioner to maintain a database of known substituted cathinones	Amend and recommit to committee 5/17/2013

© 2013 Research is current as of May 17, 2013. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

		- creates a statewide substituted cathinones surrender program	
New York	A.B. 6607	Adds 2-diphenylmethylpyrrolidine, MDAI	Referred to committee 4/12/2013
New York	A.B. 6971	Adds definition of synthetic cathinone and generic language	Referred to committee 4/29/2013
New York	S.B. 1686	Adds generic language	Referred to committee 1/9/2013
New York	S.B. 2441	Adds D2PM, MDAI	Referred to committee 1/17/2013
New York	S.B. 3469	- adds generic language - requires commissioner to maintain a database of known substituted cathinones	Amend and recommit to committee 5/13/2013
New York	S.B. 5401	- adds definition of substituted cathinone including generic language and adds penalty provisions	Referred to committee 5/16/2013
North Dakota	H.B. 1070	Adds generic language with the following as examples: 2-FMC, 3,4-DMMC, 3-FMC, 4-FMC, 4-MEC, a-PBP, a-PPP, a-PVP, buphedrone, butylone, ethcathinone, ethylone, MDPPP, MDPV, mephedrone, metamfepramone, methedrone, methylone, MOPPP, MPBP, NRG-1, pentedrone	Signed by Governor 3/27/2013
Ohio	H.B. 334	- adds 2-DPMP, D2PM, MDAI - adds generic language with the following as examples: 3-FMC, 4-FMC, a-PVP, MDPV, mephedrone, methedrone, methylone, pentedrone, pentylone	Signed by Governor; effective on signing 12/20/2012
Ohio	S.B. 301	Adds 3-FMC, 4-FMC, methylone, MDPV, mephedrone, methedrone	Signed by Governor; effective 3/13/2013 12/11/2012
Oklahoma	H.B. 2217	Adds a-PVP, pentedrone	Approved by Governor 4/29/2013
Pennsylvania	H.B. 1217	Adds generic language	Third consideration and final passage 5/7/2013

© 2013 Research is current as of May 17, 2013. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

Rhode Island	H.B. 5325	- adds BZP - adds generic language with the following as examples: a-PPP, buphedrone, ethcathinone	Referred to Senate committee 5/9/2013
Rhode Island	S.B. 454	Adds BZP and generic language with the following as examples: a-PPP, buephedrone, ethcathinone	Committee recommends measure be held for further study 3/7/2013
South Carolina	H.B. 3823	Adds 4-FMC, 4-MEC, buphedrone, butylone, BZP, MBZP, MDAI, MDPV, mephedrone, methedrone, methylone, pentedrone, pentylone, generic language	Committee report favorable 5/15/2013
South Carolina	S.B. 406	Adds 4-FMC, 4-MEC, buphedrone, butylone, BZP, MBZP, MDAI, MDPV, mephedrone, methedrone, methylone, pentedrone, pentylone, generic language	Passed Senate; in House committee 4/11/2013
South Dakota	S.B. 68	Adds 4-MBC, buphedrone, DMBDB, DMEC, DMMC, ethylethcathinone, ethylmethcathinone, eutylone, fluoroethcathinone, isopentedrone, MaPPP, MBP, MDDMA, MDMC, MDPBP, MEC, MOMC, MPBP, pentedrone, pentylone	Signed by Governor 3/6/2013
Tenn.	H.B. 12	Adds 2-DPMP	Signed by Governor 4/16/2013
Tenn.	S.B. 48	Adds 2-DPMP	Sent to dead bill file 4/1/2013
Texas	H.B. 1333	Adds 2-DPMP, D2PM, MDAI, methedrone, pentedrone, amends generic language	Placed on general state calendar 5/9/2013
Texas	S.B. 264	Adds pentedrone	Committee report sent to local & consent calendar 5/10/2013
Utah	H.B. 52	Adds 4-MEC, a-PVP, butylone, ethylone, fluoroisocathinone, MOPPP, NRG-1, pentedrone, pentylone	Signed by Governor 3/26/2013
United States	H.R. 315	Adds 3-FMC, 4-FMC, a-PPP, a-PVP, butylone, ethcathinone, ethylone, MDAI, MDPPP, metamfepramone, methedrone, methylone, MOPPP, MPBP, NRG-1	Referred to subcommittee 2/28/2013
United States	H.R. 6312	Adds 3-FMC, 4-FMC, a-PPP, a-PVP, butylone, ethcathinone, ethylone, MDAI, MDPPP, metamfepramone, methedrone, methylone, MOPPP, MPBP, NRG-1	Referred to committee 9/7/2012

© 2013 Research is current as of May 17, 2013. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

State	Reg. No.	Description	Status and Date of Last Action
Florida	312013	Adds 4-MeMABP, pentedrone	Emergency rules; enacted 12/12/2012
New York	305188	Adds 3-FMC, 4-FMC, ethcathinone, methedrone, methylone	Enacted on emergency basis 11/5/2012 Adopted 1/2/2013
North Dakota	312282	Adds generic language with the following as examples: 2-FMC, 3,4-DMMC, 3-FMC, 4-FMC, 4-MEC, a-PBP, a-PPP, a-PVP, buphedrone, butylone, ethcathinone, ethylone, MDPPP, MDPV, mephedrone, metamfepramone, methedrone, methylone, MOPPP, MPBP, NRG-1, pentedrone	Filed with Office of Legislative Council 4/1/2013
Texas	318764	Adds MDPV, mephedrone	Annual republication; effective 21 days after publication of notice 2/22/2013
Vermont	306843	Adds 2-diphenylmethylpyrrolidine, 2-DPMP, 2-FMC, 3,4-DMMC, 3-FMC, 4-EMC, 4-FMC, 4-MBC, 4-MEC, a-PBP, a-PPP, a-PVP, BZP, buphedrone, butylone, D2PM, dimethocaine, ethcathinone, ethylone, eutylone, HMMC, MaPPP, MBZP, MDAI, MDAT, MDPBP, MDPPP, metamfepramone, methedrone, MOPPP, MPBP, NRG-1, NRG-2, pentedrone, pentylone, generic language	Enacted on emergency basis; in effect until 4/20/2013 12/21/2012
Vermont	311487	Adds 2-diphenylmethylpyrrolidine, 2-DPMP, 2-FMC, 3,4-DMMC, 3-FMC, 4-EMC, 4-FMC, 4-MBC, 4-MEC, a-PBP, a-PPP, a-PVP, BZP, buphedrone, butylone, D2PM, dimethocaine, ethcathinone, ethylone, eutylone, HMMC, MaPPP, MBZP, MDAI, MDAT, MDPBP, MDPPP, metamfepramone, methedrone, MOPPP, MPBP, NRG-1, NRG-2, pentedrone, pentylone, generic language	Enacted on emergency basis 12/21/2012 Approved by Legislative Committee 2/1/2013
Vermont	317654	Adds 2-diphenylmethylpyrrolidine, 2-DPMP, 2-FMC, 3,4-DMMC, 3-FMC, 4-EMC, 4-FMC, 4-MBC, 4-MEC, a-PBP, a-PPP, a-PVP, BZP, buphedrone, butylone, D2PM, dimethocaine, ethcathinone, ethylone, eutylone, HMMC, MaPPP, MBZP, MDAI, MDAT, MDPBP, MDPPP, metamfepramone, methedrone, MOPPP, MPBP, NRG-1, NRG-2, pentedrone, pentylone, generic language	Emergency rules 2/13/2013

* Red text indicates that the state legislative session has adjourned sine die.

© 2013 Research is current as of May 17, 2013. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.